Great Lakes Advisors LLC Purchases New Holdings in Allergan plc (AGN)

Great Lakes Advisors LLC purchased a new position in shares of Allergan plc (NYSE:AGN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 8,213 shares of the company’s stock, valued at approximately $1,564,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC acquired a new stake in shares of Allergan during the 2nd quarter worth approximately $129,000. Gradient Investments LLC grew its position in shares of Allergan by 747.5% during the 3rd quarter. Gradient Investments LLC now owns 678 shares of the company’s stock worth $129,000 after buying an additional 598 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Allergan by 3,193.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock worth $165,000 after buying an additional 958 shares during the period. Aries Wealth Management acquired a new stake in shares of Allergan during the 2nd quarter worth approximately $202,000. Finally, Sawtooth Solutions LLC acquired a new stake in shares of Allergan during the 2nd quarter worth approximately $202,000. Hedge funds and other institutional investors own 78.24% of the company’s stock.

In other Allergan news, CFO Matthew M. Walsh purchased 1,000 shares of Allergan stock in a transaction that occurred on Friday, November 16th. The stock was acquired at an average price of $157.00 per share, with a total value of $157,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.36% of the company’s stock.

NYSE AGN opened at $154.00 on Thursday. Allergan plc has a 12-month low of $142.81 and a 12-month high of $197.00. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.92 and a quick ratio of 0.78. The firm has a market capitalization of $51.94 billion, a P/E ratio of 9.42, a price-to-earnings-growth ratio of 1.19 and a beta of 1.29.

Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.21. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.89 billion. During the same quarter last year, the firm posted $4.15 EPS. Allergan’s revenue was down 3.0% compared to the same quarter last year. On average, sell-side analysts expect that Allergan plc will post 16.52 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.87%. The ex-dividend date of this dividend is Friday, November 9th. Allergan’s payout ratio is currently 17.61%.

AGN has been the subject of several recent analyst reports. Guggenheim initiated coverage on shares of Allergan in a research report on Monday, October 8th. They set a “buy” rating for the company. ValuEngine raised shares of Allergan from a “strong sell” rating to a “sell” rating in a research report on Friday, September 21st. Raymond James reduced their price objective on shares of Allergan from $232.00 to $198.00 and set a “buy” rating for the company in a research report on Wednesday, October 31st. Wells Fargo & Co reaffirmed a “buy” rating on shares of Allergan in a research report on Saturday, September 15th. Finally, Leerink Swann initiated coverage on shares of Allergan in a research report on Monday, November 12th. They set an “outperform” rating and a $220.00 price objective for the company. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have given a buy rating to the stock. Allergan has an average rating of “Buy” and an average target price of $209.18.

TRADEMARK VIOLATION WARNING: This story was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://transcriptdaily.com/2018/12/06/great-lakes-advisors-llc-purchases-new-holdings-in-allergan-plc-agn.html.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Read More: Cash Flow

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply